ASTRAZENECA AND MAX PLANCK INSTITUTE ANNOUNCE RESEARCH AGREEMENT TO CREATE SATELLITE CHEMISTRY UNIT FOR CARDIOVASCULAR AND METABOLIC DISEASES
AstraZeneca today announced an agreement with the Max Planck Institute of Molecular Physiology (MPI), Germany, to establish a ‘satellite unit’ in cardiovascular and metabolic disease (CVMD), linked to AstraZeneca’s CVMD Innovative Medicines unit (iMed) in Mölndal, Sweden, to study new modalities chemistry.